TB006 is a new drug showing huge potential in the treatment of Alzheimer’s disease.

Clinical trials have shown the drug not only slows disease progression—it can also reverse signs of the devastating condition.

But is this a miracle treatment? Or are there nasty TB006 side effects to consider?

This article explores the possible side effects of TB006 based on the latest clinical research.

It also explains how to manage these adverse effects and what further research is needed.

Key Takeaways

• TB006 is an experimental drug aimed at slowing or reversing Alzheimer’s disease.
• Clinical trials have found no serious adverse effects in Alzheimer's patients. 
• The most common TB006 side effect is an infusion reaction.
• Studies are underway to review any long-term TB006 side effects.

What Are the Side Effects of TB006?

As with any new medication, understanding common TB006 side effects is crucial for ensuring drug safety.

So far, research suggests no major side effects related to TB006. 

Phase 1 clinical trials in 2021, which tested the drug's safety and side effects in healthy adults, concluded that “side effects were generally mild.”

A later clinical trial tested TB006 in people with Alzheimer’s disease. Once again, no serious adverse effects were seen among patients. 

That said, no medication is completely free from potential side effects. For TB006, an infusion reaction is the most commonly reported side effect in clinical trials. 

What is an Infusion Reaction?

An infusion reaction occurs when your body responds negatively to a medication given directly into the bloodstream through an intravenous injection.

This happens because, in some cases, the immune system mistakenly identifies the medication as harmful and attempts to fight it off.

With TB006, infusion reactions can occur because the drug is delivered directly into the blood via a vein. Fortunately, these reactions are usually mild, causing symptoms like fever, rash, or nausea.

These adverse effects typically subside within 30 to 120 minutes after the infusion ends.

In rare cases, infusion reactions can be more severe, leading to low blood pressure, dizziness, or breathing difficulties.

However, our expert medical team carefully monitors patients throughout the infusion process and can slow or stop the infusion if necessary to manage these symptoms.

What Are the Long-Term Adverse Effects of TB006?

As TB006 is still in the experimental stages, there is limited data on long-term TB006 side effects.

Current studies have focused on the drug's short-term safety and effectiveness, with results showing promising outcomes and minimal side effects. 

Ongoing clinical trials are necessary to understand the potential long-term impact on Alzheimer’s patients—and these are underway as we speak.

TrueBinding started a trial in 2022 that is looking at the long-term safety of TB006 in Alzheimer’s patients, including longer-term adverse effects. 

It’s essential for patients and caregivers to stay informed about the latest research and consult healthcare providers about any concerns related to long-term use.

FAQs: TB006 Side Effects

Q: What should I do if I experience an infusion reaction during TB006 treatment?
A: If you experience symptoms like fever, chills, or a rash during an infusion, alert your healthcare provider. They can manage these reactions by adjusting the infusion rate.

Q: Are the side effects of TB006 severe?
A: Most side effects associated with TB006 are mild, such as infusion reactions. They are generally short-lived and usually subside shortly after the infusion is complete.

Q: Can TB006 cause long-term side effects?
A: The long-term side effects of TB006 are not yet fully known, as the drug is still under study. Ongoing research aims to understand any potential long-term risks.

Conclusion: Staying Informed About TB006

TB006 is a promising treatment for Alzheimer’s disease, with the potential to slow or even reverse the condition—and with minimal adverse effects. 

Nevertheless, while most TB006 side effects are mild and manageable, it’s crucial to stay informed about the ongoing research and any updates on safety.

If you or a loved one is considering TB006, our team at Universal Neurological Care is here to provide comprehensive support and guidance. 

Contact us today to learn more about this breakthrough Alzheimer’s treatment, the cost of TB006, and how it could fit into your treatment plan.

TB006 is a groundbreaking experimental drug that slows the progression of Alzheimer’s disease.

It works by targeting one of the causes of the condition, making it highly effective at improving—and even reversing—the symptoms of dementia.

But how much does TB006 cost?

This article breaks down the costs of TB006 and explains whether you can qualify for access to the drug at Universal Neurological Care. 

Key Takeaways

• TB006 is a new drug to treat Alzheimer’s disease, offering patients new hope. 
• It works by targeting the symptoms of Alzheimer’s and can reverse the condition.
• Only two other drugs in the United States target the causes of Alzheimer’s.
• TB006 is currently only available via clinical trials or the Expanded Access Program (EAP). 
• If participating in the EAP program, you must pay for TB006 costs.
• People participating in a clinical trial for TB006 can receive the medication for free. 

How Much Does TB006 Cost?

The answer to “How much does TB006 cost?” depends on how you access treatment. 

At this stage, TB006 is experimental and still undergoing clinical trials. If you partake in a clinical trial, we have good news: access to the medication is free!

However, not everyone will qualify for these trials or wish to participate in a clinical study.

If you don’t meet the study eligibility criteria, the only other way to get TB006 is through the Expanded Access Program (EAP). We’re going to be honest: getting TB006 through the EAP is expensive.

If you decide to partake in the program, you will need to cover the following costs: 

• Manufacturing costs: TB006 is expensive to manufacture. You will need to cover all costs related to producing the medication, which have been approved by the FDA. 

• Physician fees: Patients on the EAP will need to cover physician and doctor fees. These cover the cost of your medical care as charged by your neurology clinic. 

• Assessment charges: You’ll also need to pay for any costs associated with laboratory testing and symptom assessments to monitor treatment progress.

Although the FDA approves manufacturing costs, your clinic decides physician fees and assessment charges.

Please speak with your physician to find out more, or contact our team for a breakdown of the TB006 cost at Universal Neurological Care. 

Is TB006 Worth the Cost?

Whether the TB006 Expanded Access Program is worth the cost depends on who you ask and your unique financial situation. Many believe the following benefits of TB006 justify the expense: 

• TB006 Alzheimer is one of the only drugs that targets one of the causes of Alzheimer’s disease. It binds to a protein called Galectin-3, which helps prevent toxic protein build-ups (amyloid plaques) from forming in the brain. 

• TB006 not only slows the progression of Alzheimer’s—it has the potential to reverse the disease. In a clinical trial, half of patients given TB006 for three months had a reversal of symptoms and improved memory and cognition.  

• As TB006 has the potential to reverse Alzheimer’s, it’s a one-of-its-kind treatment. It can transform the lives of patients and their loved ones. As the partner of an Alzheimer’s patient said, “How can you put a price on the person that you love?”

TB006 Cost vs. Costs of Other Alzheimer’s Drugs

Although TB006 is expensive, its price is more easily justified when considering the cost of its competitors, Lequembi and Aduhelm.

These are the only two FDA-approved drugs that, like TB006, target the causes of Alzheimer’s disease.

Leqembi costs $26,500 per year, which is out of pocket for many Alzheimer’s patients. According to the Institute for Clinical and Economic Review (a group that helps determine a fair price for new medication), this is overpriced. They suggested an appropriate cost of $8,500 to $20,600 annually.

However, it’s more affordable than Aduhelm. According to NBC News, this drug was approved in 2021 and was priced at $56,000 per year.

With almost 7 million Americans living with Alzheimer’s disease, this is disappointing news for many patients and their loved ones. 

Can I Get TB006 for Free?

The only way to get TB006 for free is to participate in a clinical trial. This grants you access to free medication throughout the study, but you’ll have to pay if you want to continue the drug after the study has been completed.

Another way to lower TB006 costs is by claiming the fees through your health insurance policy. Universal Neurological Care accepts most major insurance policies, including United Healthcare, Cigna, Tricare, Humana, and Aetna.

Please get in touch with your provider to see whether you can claim the cost of TB006 for Alzheimer’s through your health insurance company. 

TB006 Cost: FAQs

Q: How much will Leqembi cost?

A: Leqembi, one of the main competitors of TB006, costs $26,500 per year. This is over the recommended price given in the Institute of Clinical and Economic Review report.

Q: What is the cost of Alzheimer’s drugs?

A: Alzheimer’s drugs are expensive, costing up to $56,000 per year. However, you can get free access to the new experimental drug TB006 by partaking in a clinical trial. 

Q: How much does TB006 cost?

A: If paying for TB006 EAP, you must cover the cost of producing the drug, physician fees, and all laboratory tests and analyses. Contact your clinic for a full breakdown of charges. 

Am I Eligible for TB006 for Alzheimer’s?

The Expanded Access Program for TB006 isn’t available for everyone.

While there is no limit on the number of Alzheimer’s patients we can treat at Universal Neurological Care, we can only administer TB006 if you meet the following key eligibility criteria:

• Diagnosed with Alzheimer’s disease and displaying symptoms.
• Have a cognitive disability related to the condition. 
• Any other medical conditions must be stable and well-managed. 
• Unable to receive or have not responded to other treatments for Alzheimer’s disease
• Are unable to participate in clinical trials.

If you meet these criteria, contact our team. We can discuss the medication, physician fees, and laboratory testing costs for the EAP program and help you start your treatment journey.

Alzheimer’s disease is a devasting condition that affects the brain, causing severe memory loss.

Researchers have been searching for effective treatments to slow down or halt the progression of the disease for many years.

Finally, a new drug called TB006 is showing massive potential in improving the symptoms of Alzheimer’s. 

This promising treatment is now available at our clinic—the first in Florida to offer this experimental therapy.

Here, we explain what TB006 Alzheimer is, how this breakthrough Alzheimer’s treatment works, and what this can mean for patients and caregivers. 

Key Takeaways

• Alzheimer's disease is a devastating type of dementia that affects millions worldwide. 
• The brains of people with Alzheimer’s have a build-up of proteins called “amyloid plaques.” 
• TB006 is a new experimental treatment for Alzheimer’s that reduces plaques in the brain. 
• Clinical trials have shown that TB006 is highly effective at improving Alzheimer’s symptoms. 
• We are the first clinic in Florida to infuse TB006 into the brain of an Alzheimer’s patient.

What is TB006?

TB006 is a new experimental drug that can reduce the buildup of amyloid plaques in the brain. 

Amyloid plaques are predominantly made from proteins called “beta-amyloid” that clump together in the brains of people with Alzheimer’s.

The plaques disrupt communication between the brain cells (neurons) and cause inflammation, which leads to cognitive symptoms like memory loss. 

By stopping the beta-amyloid proteins from clumping together to form plaques, TB006 can reverse the symptoms of Alzheimer's.

It allows the neurons to communicate normally, improving cognition.

How Does TB006 Work?

TB006 works by binding to a protein called Galectin-3, found in abnormally high levels in the brains of people with Alzheimer’s disease. 

Galectin-3 binds to beta-amyloids, acting as a glue that causes these proteins to clump together and form amyloid plaques—but Galectin-3 cannot bind to TB006 and beta-amyloid at the same time.

By binding to Galectin-3, TB006 stops Galactin-3 from acting as a glue.

 By doing so, TB006 has the power to: 

• Prevent beta-amyloid proteins from clumping together and forming amyloid plaques. 
• May weaken the “glue” holding together existing plaques, reducing the build-up in the brain.

Why is TB006 a “Breakthrough”?

TB006 is considered a breakthrough therapy for Alzheimer’s disease for several reasons: 

1. Unlike traditional treatments that only manage symptoms, TB006 addresses one of the root causes of Alzheimer's—the amyloid plaques.

2. By reducing plaque buildup, TB006 can slow the progression of the disease, offering hope for longer periods of cognitive function and independence.

3. TB006 has the potential to clear some of the amyloid plaques that have already formed in the brain, reversing the symptoms of Alzheimer’s disease.

4. Early clinical trials have shown promising results, with many patients experiencing slower cognitive decline and improved daily functioning.

Our Clinic's Role in TB006 for Alzheimer’s

We are proud to announce that Universal Neurological Care is the first in Northeast Florida to infuse TB006 into an Alzheimer's patient.

This milestone represents a significant step forward in the fight against this debilitating disease. 

Our commitment to providing cutting-edge treatments is at the core of our mission to improve the lives of people affected by neurological disorders.

By exploring new treatment options, we can work together to combat Alzheimer's disease and offer a brighter future for patients and their families.

Stay tuned for more updates on TB006 and other exciting developments in neurological care.

TB006 for Alzheimer’s Disease: FAQs

Q: What are the results of TB006?

A: The results of TB006 are extremely promising. Alzheimer’s News Today reports that three months of TB006 reserved symptoms in almost half of patients, improving memory and cognitive function.

Q: What is Galectin-3 in Alzheimer’s disease?

A: Galectin-3 is a protein that acts as a glue, causing beta-amyloid proteins to clump together in the brain as plaques. TB006 targets Galectin-3, preventing it from sticking these other proteins together.

Q: Is TB006 safe?

A: Yes, TB006 is safe. Clinical trials on healthy individuals showed the drug was safe. The safety profile was then tested in Alzheimer’s patients, and no treatment-related adverse effects were found.

Get in Touch 

With such promising results, TB006 is an encouraging new advancement in the fight against Alzheimer's disease. 

If you or a loved one is affected by Alzheimer's disease and is interested in learning more about TB006, please contact our clinic. Our expert medical team can administer this agent to candidates who meet eligibility criteria. 

Universal Neurological Care is here to provide information, support, and guidance as you navigate this challenging journey.